News
A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.
Any patient can access Signos' system, which uses an AI platform and an off-the-shelf continuous glucose monitor, or CGM, ...
The FDA has approved Sisnos’s continuous glucose monitoring (CGM) system for consumer use beyond diabetes management, ...
The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a ...
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
Kennedy, a skeptic of weight loss drugs, has advocated for dietary and behavioral changes over GLP-1s to reverse the most ...
Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...
Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...
FDA approves Vivus' anti-obesity pill associated with significant weight loss in patients Story by Matthew Perrone, AP Health Writer July 17, 2012 at 11:56 PM UTC ...
Zacks Investment Research on MSN1d
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
Shares of Novo Nordisk NVO climbed nearly 4% on Monday after its famous obesity drug, Wegovy, received accelerated approval from the U.S. Food and Drug Administration (FDA) to treat a serious liver ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback